Allison Goldfine
Executive Director, Translational Medicine, Cardiovascular & Metabolism Novartis BioMedical Research
Seminars
Thursday 16th April 2026
Panel Discussion: Collating the Lessons Learned from FDA Approved Drugs to Inform the Future of GLP-1 Based Therapies & Ensure a Next- Generation of More Patient Centered Approaches
4:00 pm
- Broadening the therapeutic scope of GLP-1s as the new frontier for a wide range of new applications, such as cardiovascular disease, neurodegenerative disorders and ageing, offering patients a more comprehensive approach to health beyond just weight loss
- Enhancing drug delivery for patient success to improve patient adherence through less frequent administration, including once-a-month injections and oral medications, providing a convenient and less intrusive treatment experience that supports longterm adherence
- Integrating a complementary ecosystem of care for collaborative approach of chronic drugs, advanced combinations, and procedural solutions that work together to create a personalized treatment plan for each patient, maximizing chances of achieving sustainable metabolic health
